Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Watson Oxytrol Dry Mouth Profile Gives Overactive Bladder Patch Marketing Edge

Executive Summary

Watson's Oxytrol dry mouth side effect profile gives the overactive bladder patch a marketing edge over oral anticholinergic agents
Advertisement

Related Content

Watson Oxytrol Launch Focus On Heavy Sampling Has Delayed Rx Uptake
Watson Oxytrol Launch Focus On Heavy Sampling Has Delayed Rx Uptake
Oxytrol Medicaid Reimbursement Expected In 75% Of States At Launch
Oxytrol Medicaid Reimbursement Expected In 75% Of States At Launch
Watson Oxytrol Launch To Focus On Specialists; CSO To Target Primary Care
Watson Oxytrol Approval Expected In 2003; Patch Is “Not Approvable” At FDA
Watson Oxytrol Approval Expected In 2003; Patch Is “Not Approvable” At FDA
Advertisement
UsernamePublicRestriction

Register

PS041374

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel